Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Martin W. G. Brinkhof; Matthias Egger; Andrew Boulle; Margaret May; Mina Hosseinipour; Eduardo Sprinz; Paula Braitstein; François Dabis; Peter Reiss; David R. Bangsberg; Martin Rickenbach; Jose M. Miro; Landon Myer; Amanda Mocroft; Denis Nash; Olivia Keiser; Margaret Pascoe; Stefaan van der Borght; Mauro Schechter

doi:10.1086/522986

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Martin W. G. Brinkhof
, Matthias Egger
, Andrew Boulle
, Margaret May
, Mina Hosseinipour
, Eduardo Sprinz
, Paula Braitstein
, François Dabis
, Peter Reiss
, David R. Bangsberg
, Martin Rickenbach
, Jose M. Miro
, Landon Myer
, Amanda Mocroft
, Denis Nash
, Olivia Keiser
, Margaret Pascoe
, Stefaan van der Borght
, Mauro Schechter

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

Original language	English
Pages (from-to)	1518-1521
Journal	Clinical infectious diseases
Volume	45
Issue number	11
DOIs	https://doi.org/10.1086/522986
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1086/522986

Cite this

Brinkhof, M. W. G., Egger, M., Boulle, A., May, M., Hosseinipour, M., Sprinz, E., Braitstein, P., Dabis, F., Reiss, P., Bangsberg, D. R., Rickenbach, M., Miro, J. M., Myer, L., Mocroft, A., Nash, D., Keiser, O., Pascoe, M., van der Borght, S., & Schechter, M. (2007). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clinical infectious diseases, 45(11), 1518-1521. https://doi.org/10.1086/522986

@article{6235935f461242789003a1db672043a4,

title = "Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries",

abstract = "We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95\% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95\% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings",

author = "Brinkhof, \{Martin W. G.\} and Matthias Egger and Andrew Boulle and Margaret May and Mina Hosseinipour and Eduardo Sprinz and Paula Braitstein and Fran{\c c}ois Dabis and Peter Reiss and Bangsberg, \{David R.\} and Martin Rickenbach and Miro, \{Jose M.\} and Landon Myer and Amanda Mocroft and Denis Nash and Olivia Keiser and Margaret Pascoe and \{van der Borght\}, Stefaan and Mauro Schechter",

year = "2007",

doi = "10.1086/522986",

language = "English",

volume = "45",

pages = "1518--1521",

journal = "Clinical infectious diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "11",

}

Brinkhof, MWG, Egger, M, Boulle, A, May, M, Hosseinipour, M, Sprinz, E, Braitstein, P, Dabis, F, Reiss, P, Bangsberg, DR, Rickenbach, M, Miro, JM, Myer, L, Mocroft, A, Nash, D, Keiser, O, Pascoe, M, van der Borght, S & Schechter, M 2007, 'Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries', Clinical infectious diseases, vol. 45, no. 11, pp. 1518-1521. https://doi.org/10.1086/522986

TY - JOUR

T1 - Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

AU - Brinkhof, Martin W. G.

AU - Egger, Matthias

AU - Boulle, Andrew

AU - May, Margaret

AU - Hosseinipour, Mina

AU - Sprinz, Eduardo

AU - Braitstein, Paula

AU - Dabis, François

AU - Reiss, Peter

AU - Bangsberg, David R.

AU - Rickenbach, Martin

AU - Miro, Jose M.

AU - Myer, Landon

AU - Mocroft, Amanda

AU - Nash, Denis

AU - Keiser, Olivia

AU - Pascoe, Margaret

AU - van der Borght, Stefaan

AU - Schechter, Mauro

PY - 2007

Y1 - 2007

N2 - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

AB - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

U2 - 10.1086/522986

DO - 10.1086/522986

M3 - Article

C2 - 17990236

SN - 1058-4838

VL - 45

SP - 1518

EP - 1521

JO - Clinical infectious diseases

JF - Clinical infectious diseases

IS - 11

ER -

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this